Cellectar Biosciences Inc (CLRB)

Sector:
CONSUMER DISCRETIONARY
Industry:
CONSUMER SERVICES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
James V. Caruso
Employees:
10
3301 AGRICULTURE DRIVE, MADISON, WI 53716
(608) 441-8120

Cellectar Biosciences, Inc. focuses on the discovery, development, and commercialization of drugs for cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies.

Data derived from most recent annual or quarterly report
Market Cap 15.877 Million Shares Outstanding9.741 Million Avg 30-day Volume 49.773 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-2.75
Price to Revenue0.0 Debt to Equity0.0 EBITDA-31.231 Million
Price to Book Value0.083 Operating Margin0.0 Enterprise Value4.74 Million
Current Ratio1.991 EPS Growth0.297 Quick Ratio1.823
1 Yr BETA -0.4712 52-week High/Low 6.76 / 0.34 Profit Margin0.0
Operating Cash Flow Growth-19.7328 Altman Z-Score-5.1336 Free Cash Flow to Firm -20.06 Million
View SEC Filings from CLRB instead.

View recent insider trading info

Cellectar Biosciences Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding CLRB (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CLRB

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-03-16 by SHUSTOV ANDREI
  • 3: filed on 2023-03-16 by SHUSTOV ANDREI
  • 4: filed on 2023-01-18 by LONGCOR JARROD
  • 4: filed on 2023-01-18 by CARUSO JAMES V
  • 4: filed on 2023-01-18 by KOLEAN CHAD J
  • 4: filed on 2022-12-15 by LEA DARRELL SHANE
  • 3: filed on 2022-12-15 by LEA DARRELL SHANE
  • 4: filed on 2022-08-01 by SWIRSKY DOUGLAS J
  • 4: filed on 2022-08-01 by NEIS JOHN
  • 4: filed on 2022-08-01 by LOREN STEFAN

    • Events (8k)

  • 8-K: filed on 2023-05-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-04:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
  • 8-K: filed on 2022-12-02:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-25:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-22:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-13:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-05:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-07-21:
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    SHUSTOV ANDREI SENIOR VICE PRESIDENT, MEDICAL

    • Officer
    		 0 2023-02-15 2

    CARUSO JAMES V PRESIDENT AND CEO

    • Officer
    • Director
    		 261,000 2023-01-17 1

    LONGCOR JARROD CHIEF OPERATING OFFICER

    • Officer
    		 144,000 2023-01-17 1

    KOLEAN CHAD J CHIEF FINANCIAL OFFICER

    • Officer
    		 104,000 2023-01-17 1

    LEA DARRELL SHANE CHIEF COMMERCIAL OFFICER

    • Officer
    		 0 2022-11-21 2

    DRISCOLL FREDERICK W

    • Director
    		 7,800 2022-06-24 1

    NEIS JOHN

    • Director
    		 7,800 2022-06-24 1

    SWIRSKY DOUGLAS J

    • Director
    		 11,700 2022-06-24 1

    LOREN STEFAN

    • Director
    		 7,800 2022-06-24 1

    CHANAN-KHAN ASHER

    • Director
    		 7,800 2022-06-24 1

    ELEFANT DOV CHIEF FINANCIAL OFFICER

    • Officer
    		 422,000 2022-01-25 0

    FRIEND JOHN E. II CHIEF MEDICAL OFFICER

    • Officer
    		 330,000 2021-03-04 0

    HILL STEPHEN A

    • Director
    		 0 2020-06-24 0

    GRACHEV IGOR D CHIEF MEDICAL OFFICER

    • Officer
    		 0 2020-01-06 0

    BERNHARDT CHARLES THOMAS III INTERIM CFO

    • Officer
    		 0 2019-03-09 0

    POSNER BRIAN M CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2019-01-17 0

    HAMILL JOHN P. INTERIM CFO

    • Officer
    		 0 2017-09-05 0

    HERTZBERG RICHARD

    • SIGNIFICANT OWNER
    		 No longer subject to file 2016-08-09 0

    WEICHERT JAMEY P CHIEF SCIENTIFIC OFFICER

    • Officer
    		 0 2016-05-12 0

    BERNS PAUL L

    • Director
    		 234,742 2016-04-20 0

    WISCONSIN ALUMNI RESEARCH FOUNDATION

    • 10% Owner
    		 469,484 2016-04-14 0

    AWM INVESTMENT COMPANY, INC.

    • 10% Owner
    		 No longer subject to file 2015-12-30 0

    GENN JOHN PATRICK VP OF BUSINESS DEVELOPMENT

    • Officer
    		 0 2015-02-26 0

    MARXE AUSTIN W & GREENHOUSE DAVID M

    • 10% Owner
    		 1,142,368 2015-02-03 0

    SZAKACS CAMERON VP OF CLINICAL DEVELOPMENT

    • Officer
    		 0 2014-11-24 0

    PEDDER SIMON PRESIDENT AND CEO

    • Officer
    • Director
    		 290,878 2014-08-20 0

    CORMORANT ASSET MANAGEMENT, LLC

    CHEN BIHUA

    CORMORANT GLOBAL HEALTHCARE GP, LLC

    CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP

    • Director
    • 10% Owner
    		 530,000 2014-08-15 0

    MCNEIL KATHRYN M SEE REMARKS

    • Officer
    		 0 2014-08-14 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    CELLECTAR BIOSCIENCES INC CLRB 2023-06-02 22:15:04 UTC -7.7311 12.7911 100000
    CELLECTAR BIOSCIENCES INC CLRB 2023-06-02 21:45:04 UTC -7.7311 12.7911 100000
    CELLECTAR BIOSCIENCES INC CLRB 2023-06-02 21:15:04 UTC -7.7311 12.7911 100000
    CELLECTAR BIOSCIENCES INC CLRB 2023-06-02 20:45:03 UTC -7.7311 12.7911 100000
    CELLECTAR BIOSCIENCES INC CLRB 2023-06-02 20:15:05 UTC -7.7311 12.7911 100000
    CELLECTAR BIOSCIENCES INC CLRB 2023-06-02 19:45:04 UTC -7.7311 12.7911 100000
    CELLECTAR BIOSCIENCES INC CLRB 2023-06-02 19:15:04 UTC -7.7311 12.7911 100000
    CELLECTAR BIOSCIENCES INC CLRB 2023-06-02 18:45:04 UTC -7.7311 12.7911 100000
    CELLECTAR BIOSCIENCES INC CLRB 2023-06-02 18:15:04 UTC -7.7311 12.7911 100000
    CELLECTAR BIOSCIENCES INC CLRB 2023-06-02 17:45:03 UTC -7.7311 12.7911 100000
    CELLECTAR BIOSCIENCES INC CLRB 2023-06-02 17:15:04 UTC -7.7311 12.7911 100000
    CELLECTAR BIOSCIENCES INC CLRB 2023-06-02 16:45:03 UTC -7.7311 12.7911 100000
    CELLECTAR BIOSCIENCES INC CLRB 2023-06-02 16:15:04 UTC -7.7311 12.7911 100000
    CELLECTAR BIOSCIENCES INC CLRB 2023-06-02 15:45:04 UTC -7.7311 12.7911 100000
    CELLECTAR BIOSCIENCES INC CLRB 2023-06-02 15:15:03 UTC -7.7311 12.7911 100000
    CELLECTAR BIOSCIENCES INC CLRB 2023-06-02 14:45:04 UTC -7.5282 12.5982 100000
    CELLECTAR BIOSCIENCES INC CLRB 2023-06-02 14:15:03 UTC -7.5282 12.5982 100000
    CELLECTAR BIOSCIENCES INC CLRB 2023-06-02 13:45:03 UTC -7.5282 12.5982 100000
    CELLECTAR BIOSCIENCES INC CLRB 2023-06-02 13:15:04 UTC -7.5282 12.5982 100000
    CELLECTAR BIOSCIENCES INC CLRB 2023-06-02 12:45:03 UTC -7.5282 12.5982 100000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments